This product is a CRISPR/Cas9-edited polyclonal knockout cell population targeting the IKBKB gene in the 769-P human clear cell renal cell carcinoma cell line. The loss-of-function model is generated through targeted gene disruption, resulting in a heterogeneous pool of cells carrying diverse IKBKB mutations that collectively ablate IKK?? protein function. The polyclonal format avoids clonal selection artifacts and enables robust population-level analyses of IKBKB-dependent signaling in a genetically defined tumor cell background.
The 769-P host cell line was originally established from a primary clear cell renal cell carcinoma of a 63-year-old female patient. These adherent epithelial cells harbor an endogenous VHL mutation, characteristic of the classic clear cell carcinoma subtype, and are widely used as a model system for VHL-mutant renal cell carcinoma biology. The 769-P line retains key oncogenic features, including constitutive activation of hypoxia and proliferation pathways, making it a relevant platform for dissecting tumor-specific signaling dependencies.
IKBKB encodes IKK??, the catalytic subunit of the I??B kinase complex. Upon stimulation by upstream activators including TNF??, IL-1??, TAK1, TRAF2, TRAF6, and RIP1, IKK?? associates with IKK?? and NEMO to phosphorylate I??B?? (NFKBIA), marking it for proteasomal degradation. This liberates NF-??B dimers, primarily p65 (RELA) and p50 (NFKB1), to translocate to the nucleus and induce expression of pro-inflammatory cytokines (IL-6, TNF??), anti-apoptotic factors (BCL2, BCL-XL), and cell cycle regulators (cyclin D1). IKK?? thus constitutes a central node in canonical NF-??B-driven inflammatory and survival signaling.
In the 769-P VHL-mutant renal cell carcinoma background, IKBKB disruption enables direct interrogation of NF-??B-dependent tumor cell features. Dysregulated NF-??B activity often contributes to renal carcinoma proliferation, survival, and inflammatory microenvironment modulation. This polyclonal knockout system allows rigorous assessment of IKK??-mediated phenotypes??including cytokine secretion, apoptosis resistance, and transcriptional changes??without clonal bias. The VHL-null context additionally facilitates exploration of cross-regulation between hypoxia pathways and the IKK/NF-??B axis.
Key research applications include Western blotting for phospho-I??B?? and total I??B??, NF-??B luciferase reporter assays, ELISA for secreted cytokines, flow cytometric apoptosis detection, RT-qPCR of NF-??B target genes, immunofluorescence for p65 nuclear localization, and co-immunoprecipitation of IKK components. These methods enable studies of inflammatory signaling, IKK?? inhibitor screening, drug resistance, and renal carcinoma biology. For further details or technical assistance, please contact Ascent Research.
